Skip to main content

Table 1 Baseline characteristics of biologic-naïve and TNFi-exposed participants

From: Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

 

Biologic naïve (N = 574)

TNFi-exposed (N = 2451)

p-value

n

%

n

%

Female, n (%)

402

70

1810

73.9

0.06

Rheumatoid factor positive (n = 444:1925)

386

84.9

1625

82

0.012

Cyclic citrullinated peptide (CCP) + ve (n = 13:109)

10

76.9

74

67.9

0.51

No. of prior DMARDs

    

< 0.001

 None

31

5.4

200

8.2

 

 1

95

16.6

53

2.2

 

 2

154

26.5

132

5.4

 

 3

115

20

408

16.7

 

 4

92

16

628

25.6

 

 5

59

10.3

583

23.8

 

 6–10

28

4.9

447

18.2

 

Ever used methotrexate

493

85.9

2185

89.2

0.03

Ever used prednisolone

318

55.4

1933

78.9

< 0.001

Current smoker

78

13.6

341

14.1

0.76

Prior malignancy

44

7.4

94

3.7

< 0.001

 

N

Mean

SD

N

Mean

SD

p-value

Age (years)

574

62.4

12.3

2451

55.7

12.4

< 0.001

HAQ (Range 0–3)

572

1.1

0.7

2443

1.2

0.7

< 0.001

AQoL (Range − 0.04 – 1)

572

0.6

0.3

2438

0.5

0.2

< 0.001

EQ5D (UK) (Range − 0.59 - 1)

560

0.7

0.3

2405

0.6

0.3

< 0.001

PCS (Range 0–100)

556

35.1

11.2

2374

32.1

11

< 0.001

MCS (Range 0–100)

556

48.3

11.6

2374

46.5

11.9

0.001

ESR (Range 2–109)

150

26.3

22.1

1259

33.2

25.1

0.002

CRP (Range 0.4–128)

155

17.1

22.6

1260

25.3

30.1

0.001

Joint count (Range 0–50)

150

12.2

12.8

1323

23.5

11

0.001

Years since RA diagnosis

566

13.8

11.6

2444

14.1

10.6

0.1